A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Oct 13, 2016

FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN

North Brunswick, N.J. and Tokyo, October, 12, 2016 – Chromocell Corporation and Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Read more about FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Oct 11, 2016

Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care　-Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER-

NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...

Read more about Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care　-Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER-
Oct 11, 2016

Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care

Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER

NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...

Read more about Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care
Oct 7, 2016

Astellas Filed Lawsuit against Patent Infringement of Myrbetriq® in the United States

Tokyo, Japan, October 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) and its subsidiaries jointly filed a lawsuit against Actavis Elizabeth LLC...

Read more about Astellas Filed Lawsuit against Patent Infringement of Myrbetriq® in the United States
Oct 5, 2016

Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund

Tokyo, October 5, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the "Flying Star Fund," a social contribution fund run by its employees,...

Read more about Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund
Sep 28, 2016

Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area

Osaka and Tokyo (Japan), September 28, 2016 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office:...

Read more about Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area
Sep 28, 2016

Astellas Receives Approval for Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan

Tokyo, September 28, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it received a marketing approval of Kiklin® Granules 86.2%...

Read more about Astellas Receives Approval for Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan
Sep 28, 2016

Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination-

Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:...

Read more about Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination-
Sep 19, 2016

Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients

SAN DIEGO and TOKYO - September 19, 2016 – Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. (TOKYO: 4503) today announced topline results from a randomized, double-blind,...

Read more about Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients
Sep 16, 2016

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year

Tokyo, September 16, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year as an index...

Read more about Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts